TY - JOUR
T1 - A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment
AU - Alberti, Diego
AU - Protti, Nicoletta
AU - Toppino, Antonio
AU - Deagostino, Annamaria
AU - Lanzardo, Stefania
AU - Bortolussi, Silva
AU - Altieri, Saverio
AU - Voena, Claudia
AU - Chiarle, Roberto
AU - Geninatti Crich, Simonetta
AU - Aime, Silvio
N1 - Funding Information:
This research was founded by the AIRC Investigator Grant IG2013 , by the University of Torino (project code D15E11001710003 ), by the University of Genova (Progetto San Paolo; Title: Validazione di molecole per il rilascio tumore specifico di farmaci e la valutazione contestuale della risposta mediante imaging funzionale), by MIUR (PRIN 2012 code 2012SK7ASN ) and by Consorzio Interuniversitario di Ricerca in Chimica dei Metalli dei Sistemi Biologici (CIRCMSB) . This research was performed in the framework of the EU COST Action TD1004.
Publisher Copyright:
© 2015 Elsevier Inc..
PY - 2015
Y1 - 2015
N2 - This study aims at developing an innovative theranostic approach for lung tumor and metastases treatment, based on Boron Neutron Capture Therapy (BNCT). It relies on to the use of low density lipoproteins (LDL) as carriers able to maximize the selective uptake of boron atoms in tumor cells and, at the same time, to quantify the in vivo boron distribution by magnetic resonance imaging (MRI). Tumor cells uptake was initially assessed by ICP-MS and MRI on four types of tumor (TUBO, B16-F10, MCF-7, A549) and one healthy (N-MUG) cell lines. Lung metastases were generated by intravenous injection of a Her2. + breast cancer cell line (i.e. TUBO) in BALB/c mice and transgenic EML4-ALK mice were used as primary tumor model. After neutron irradiation, tumor growth was followed for 30-40. days by MRI. Tumor masses of boron treated mice increased markedly slowly than the control group.
AB - This study aims at developing an innovative theranostic approach for lung tumor and metastases treatment, based on Boron Neutron Capture Therapy (BNCT). It relies on to the use of low density lipoproteins (LDL) as carriers able to maximize the selective uptake of boron atoms in tumor cells and, at the same time, to quantify the in vivo boron distribution by magnetic resonance imaging (MRI). Tumor cells uptake was initially assessed by ICP-MS and MRI on four types of tumor (TUBO, B16-F10, MCF-7, A549) and one healthy (N-MUG) cell lines. Lung metastases were generated by intravenous injection of a Her2. + breast cancer cell line (i.e. TUBO) in BALB/c mice and transgenic EML4-ALK mice were used as primary tumor model. After neutron irradiation, tumor growth was followed for 30-40. days by MRI. Tumor masses of boron treated mice increased markedly slowly than the control group.
KW - Boron Neutron Capture Therapy (BNCT)
KW - Carboranes
KW - Low density lipoproteins (LDL)
KW - MRI
KW - Theranostic agents
UR - http://www.scopus.com/inward/record.url?scp=84933527978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933527978&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2014.12.004
DO - 10.1016/j.nano.2014.12.004
M3 - Article
C2 - 25596074
AN - SCOPUS:84933527978
SN - 1549-9634
VL - 11
SP - 741
EP - 750
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 3
ER -
